DDInter1925 DDInter899
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Vemurafenib {u} (Compound) resembles {v} (Compound) Etoricoxib
Vemurafenib {u} (Compound) treats {v} (Disease) skin cancer
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
Vemurafenib {u} (Compound) upregulates {v} (Gene) DHRS12
Vemurafenib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Vemurafenib {u} (Compound) downregulates {v} (Gene) CLPP
Vemurafenib {u} (Compound) causes {v} (Side Effect) Eosinophilia
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Vemurafenib (Compound) resembles Etoricoxib (Compound)
Vemurafenib (Compound) treats skin cancer (Disease)
Vemurafenib (Compound) binds CYP3A4 (Gene)
Vemurafenib (Compound) upregulates DHRS12 (Gene)
Vemurafenib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Vemurafenib (Compound) downregulates CLPP (Gene)
Vemurafenib (Compound) causes Eosinophilia (Side Effect)
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan